Herrmann, Joerg
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL 1169952-03)
Article History
First Online: 21 April 2016
Compliance with Ethical Standards
:
: Joerg Herrmann participated in the 2014 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squibb.
: This article does not contain any studies with human or animal subjects performed by any of the authors.